GOLM1 and metabolic dysfunction-associated steatohepatitis: The gradual increase of serum GP73 in parallel with the severity of hepatic necroinflammation implicated that serum GP73 could be a potential biomarker for identifying NASH patients with moderate or severe activity from those normal or mild activity.